Vertex Pharmaceutica
VRTX
Delayed Nasdaq - 05/25 10:00:00 pm
157.5USD
+0.34%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 20172018
Sales2 1742 804
EBITDA611930
Operating profit (EBIT)550885
Pre-Tax Profit (EBT)--
Net income263583
EPS ( $ )1,042,24
Dividend per Share ( $ )--
Yield--
Announcement Date01/31/2018
10:00pm
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 20172018
Debt--
Finance1 5252 561
Operating income (EBITDA)611930
Leverage
(Debt/EBITDA)
--
Capital Expenditure99,4107
Book Value Per Share (BVPS)8,06 $10,7 $
Cash Flow per Share3,34 $4,14 $
Announcement Date01/31/2018
10:00pm
-
Balance Sheet Analysis
Financial Ratios
Size 2018e 2019e
Capitalization 40 136 M$ -
Entreprise Value (EV) 37 575 M$ 36 598 M$
Valuation 2018e 2019e
P/E ratio (Price / EPS) 70,4x 45,8x
Capitalization / Revenue 14,3x 11,7x
EV / Revenue 13,4x 10,7x
EV / EBITDA 40,4x 28,2x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 14,8x 11,4x
Profitability 2018e 2019e
Operating Margin (EBIT / Sales) 31,6% 37,2%
operating Leverage (Delta EBIT / Delta Sales) 2,10x 2,00x
Net Margin (Net Profit / Revenue) 20,8% 24,9%
ROA (Net Profit / Asset) 17,1% 19,8%
ROE (Net Profit / Equities) 33,0% 35,5%
Rate of Dividend - -
Balance Sheet Analysis 2018e 2019e
CAPEX / CA   3,82% 2,86%
Cash Flow / Sales 37,7% 44,1%
Capital Intensity (Assets / Sales) 1,22x 1,26x
Financial Leverage (Net Debt / EBITDA) -2,75x -2,73x
Price Earning Ratio
BNA & Dividende